The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•20 April 2026•

1 min read

Volition Launches rNuQ™ Webshop to Expand Product Range in Epigenetics Market

Key Facts

1VolitionRx Limited launched a webshop offering a range of ready-to-use recombinant nucleosomes (rNuQ).

2The products were developed over the past 10 years by the multi-national epigenetics company.

VolitionRx Limited (NYSE AMERICAN: VNRX) has officially launched a direct-to-customer webshop featuring its proprietary range of ready-to-use recombinant nucleosomes (rNuQ). These specialized products are the result of over 10 years of intensive research and development by the multi-national epigenetics company. The launch aims to broaden the company's commercial reach and provide researchers with easier access to high-quality epigenetic tools. By establishing this e-commerce presence, Volition is transitioning its long-term scientific developments into a scalable commercial revenue stream. This move is seen as a positive step for the micro-cap biotech firm in monetizing its intellectual property. The webshop represents a strategic effort to diversify the company's market presence within the global biotechnology sector.